Last reviewed · How we verify
CBD powder form capsule
CBD powder form capsule is a Cannabinoid Small molecule drug developed by Hadassah Medical Organization. It is currently in Phase 1 development. Also known as: Cannabidiol solid dosage form.
CBD interacts with the endocannabinoid system, primarily affecting CB1 and CB2 receptors, though its exact mechanism remains complex and not fully elucidated.
CBD powder form capsules are being studied in clinical trials for pain management. The mechanism of CBD is currently unknown, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CBD powder form capsule |
|---|---|
| Also known as | Cannabidiol solid dosage form |
| Sponsor | Hadassah Medical Organization |
| Drug class | Cannabinoid |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
Cannabidiol (CBD) modulates the endocannabinoid system through multiple pathways, including indirect effects on CB1 and CB2 receptors, as well as interactions with serotonin receptors, TRPV1 channels, and other targets. Unlike THC, CBD does not produce intoxicating effects and may have anti-inflammatory, anxiolytic, and neuroprotective properties.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBD powder form capsule CI brief — competitive landscape report
- CBD powder form capsule updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI
Frequently asked questions about CBD powder form capsule
What is CBD powder form capsule?
How does CBD powder form capsule work?
Who makes CBD powder form capsule?
Is CBD powder form capsule also known as anything else?
What drug class is CBD powder form capsule in?
What development phase is CBD powder form capsule in?
Related
- Drug class: All Cannabinoid drugs
- Manufacturer: Hadassah Medical Organization — full pipeline
- Also known as: Cannabidiol solid dosage form
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing